Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
NEW YORK, March 28, 2017 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”), a corporation headquartered in Cambridge, Massachusetts and incorporated in Delaware, and certain of its senior officers and executives. If you purchased Sarepta stock between October 1, 2015 and January 15, 2016, you are encouraged to contact a Scott+Scott attorney toll free at (844) 818-6980 for more information.
Sarepta is a biopharmaceutical company focused on the discovery and development of therapeutics for the treatment of rare, infectious and other diseases. The Company developed the drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease. Eteplirsen is designed to increase the underlying cause of DMD by enabling production of the protein dystrophin.
In October 2015, Sarepta told the public, including investors, that clinical trials of eteplirsen had demonstrated “dystrophin production in nearly all patients,” “dystrophin intensity that was statistically significant,” and “dystrophin production [that] was in fact robust.”
On January 15, 2016, the U.S. Food and Drug Administration (“FDA”) released an analysis of Sarepta’s eteplirsen trials. Among other things, the FDA pointed out that DMD experts had stated that “induction of approximately 10% of normal dystrophin levels sets a minimum level to confer measurable clinic benefit.” Dystrophin levels after Sarepta’s eteplirsen treatment were only reported to be about 0.9% of normal. Thus, the FDA report disclosed that eteplirsen had not shown the “significant” increase in dystrophin that Sarepta had touted.
On this news, the price of Sarepta common stock plummeted more than 54%, from $31.63 on January 14, 2016 to close at $14.28 on January 15, 2016.
What You Can Do
If you purchased Sarepta stock between October 1, 2015 and January 15, 2016 and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.
CONTACT: Rhiana Swartz Scott+Scott, Attorneys at Law, LLP (844) 818-6980 [email protected]
